Dr Reddy's To Collaborate With American Pharma Eli Lilly To Produce Baricitinib For Covid Treatment In India
ABP NewsHyderabad: On Wednesday, Dr. Reddy's Laboratories Ltd announced that it has entered into a royalty-free, non-exclusive voluntary licensing agreement with Eli Lilly and Company for the manufacture and commercialization of baricitinib in India. Our collaboration with Lilly will help us make yet another treatment option available to patients in India," said Deepak Sapra, Chief Executive Officer, API and Services, Dr. Reddy's Laboratories according to IANS. Eli Lilly and Company had on May 10th announced voluntary licensing agreements with Sun Pharma, Cipla and Lupin to expedite the availability of Baricitinib for treatment of Covid-19 patients in India. He added, "We're excited to extend our strategic partnership with Gland Pharma whose hard work, in collaboration with the team at Dr. Reddy's, has enabled the execution of this launch."
History of this topic
Dr. Reddy's Launches First-in-Class Constipation Drug in India
The Hindu
Dr. Reddy’s launches palbociclib to widen access to high-quality breast cancer drug
Deccan ChronicleDr. Reddy’s, Prestige BioPharma ink pact on cancer drug
The Hindu)
India Gives Emergency Use Approval to Eli Lilly Gets for Covid-19 Antibody Drug
News 18)
Eli Lilly inks pacts for COVID-19 drug Baricitinib with Torrent Pharma, Dr Reddy's and MSN Labs
Firstpost)
Dr Reddy's Inks Licensing Pact with Eli Lilly for Covid-19 Treatment Drug
News 18
Eli Lilly signs licensing pact with Cipla, Sun, Lupin for Covid-19 drug
Business Standard)
Dr Reddy's Labs Rally 14 per cent Intra-Day, Becomes 2nd Most Valuable Indian Pharma Company Again
News 18)
Dr Reddy's Labs to acquire branded generics business of Wockhardt for Rs 1,850 cr; deal to help scale-up presence in home market
FirstpostDiscover Related
